Loukas A, Papadourakis M, Panagiotopoulos V, Zarmpala A, Chontzopoulou E, Christodoulou S
Int J Mol Sci. 2024; 25(9).
PMID: 38732267
PMC: 11084538.
DOI: 10.3390/ijms25095047.
Lu W, Liu Y, Gao Y, Geng Q, Gurbani D, Li L
J Med Chem. 2023; 66(5):3356-3371.
PMID: 36826833
PMC: 11190964.
DOI: 10.1021/acs.jmedchem.2c01834.
Turvey S, McPhillie M, Kearney M, Muench S, Simmons K, Fishwick C
RSC Med Chem. 2022; 13(4):360-374.
PMID: 35647546
PMC: 9020618.
DOI: 10.1039/d1md00300c.
Liu R, Verma N, Henderson J, Zhan S, Shen J
RSC Med Chem. 2022; 13(1):54-63.
PMID: 35224496
PMC: 8792824.
DOI: 10.1039/d1md00277e.
Cho H, Hah J
Biomedicines. 2021; 9(10).
PMID: 34680547
PMC: 8533360.
DOI: 10.3390/biomedicines9101431.
IGF1R regulates retrograde axonal transport of signalling endosomes in motor neurons.
Fellows A, Rhymes E, Gibbs K, Greensmith L, Schiavo G
EMBO Rep. 2020; 21(3):e49129.
PMID: 32030864
PMC: 7054680.
DOI: 10.15252/embr.201949129.
Potent Pyrimidine and Pyrrolopyrimidine Inhibitors of Testis-Specific Serine/Threonine Kinase 2 (TSSK2).
Hawkinson J, Sinville R, Mudaliar D, Shetty J, Ward T, Herr J
ChemMedChem. 2017; 12(22):1857-1865.
PMID: 28952188
PMC: 5962959.
DOI: 10.1002/cmdc.201700503.
Synthesis and fungicidal activity of pyrazole derivatives containing 1,2,3,4-tetrahydroquinoline.
Lei P, Zhang X, Xu Y, Xu G, Liu X, Yang X
Chem Cent J. 2016; 10:40.
PMID: 27382411
PMC: 4932680.
DOI: 10.1186/s13065-016-0186-8.
ALK and ROS1 as a joint target for the treatment of lung cancer: a review.
Puig de la Bellacasa R, Karachaliou N, Estrada-Tejedor R, Teixido J, Costa C, Borrell J
Transl Lung Cancer Res. 2015; 2(2):72-86.
PMID: 25806218
PMC: 4369855.
DOI: 10.3978/j.issn.2218-6751.2013.03.1.
Identification and structure-function analysis of subfamily selective G protein-coupled receptor kinase inhibitors.
Homan K, Larimore K, Elkins J, Szklarz M, Knapp S, Tesmer J
ACS Chem Biol. 2014; 10(1):310-9.
PMID: 25238254
PMC: 4301037.
DOI: 10.1021/cb5006323.
A highly selective dual insulin receptor (IR)/insulin-like growth factor 1 receptor (IGF-1R) inhibitor derived from an extracellular signal-regulated kinase (ERK) inhibitor.
Anastassiadis T, Duong-Ly K, Deacon S, Lafontant A, Ma H, Devarajan K
J Biol Chem. 2013; 288(39):28068-77.
PMID: 23935097
PMC: 3784719.
DOI: 10.1074/jbc.M113.505032.
Enzyme kinetics and interaction studies for human JNK1β1 and substrates activating transcription factor 2 (ATF2) and c-Jun N-terminal kinase (c-Jun).
Figuera-Losada M, LoGrasso P
J Biol Chem. 2012; 287(16):13291-302.
PMID: 22351776
PMC: 3339953.
DOI: 10.1074/jbc.M111.323766.
Analysis of conditions affecting auto-phosphorylation of human kinases during expression in bacteria.
Shrestha A, Hamilton G, ONeill E, Knapp S, Elkins J
Protein Expr Purif. 2011; 81(1):136-143.
PMID: 21985771
PMC: 3445812.
DOI: 10.1016/j.pep.2011.09.012.
Understanding the specificity of a docking interaction between JNK1 and the scaffolding protein JIP1.
Yan C, Kaoud T, Lee S, Dalby K, Ren P
J Phys Chem B. 2011; 115(6):1491-502.
PMID: 21261310
PMC: 3042137.
DOI: 10.1021/jp1073522.
Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.
Li R, Pourpak A, Morris S
J Med Chem. 2009; 52(16):4981-5004.
PMID: 19610618
PMC: 2888655.
DOI: 10.1021/jm9002395.
